You can't give this stuff away! Oh wait, BioSante Pharmaceuticals
Yesterday, the drugmaker licensed its pancreas and prostate cancer vaccine to Aduro BioTech to use it in combination with Aduro's vaccine CRS-207.
I love a good platform drugmaker. The ability to make money over and over again by licensing out a technology is a blessing for investors that don't have to take a dilution hit every time the company needs more cash.
Unfortunately, there doesn't seem to be any upfront cash for BioSante in the deal. Compare that to Seattle Genetics
BioSante is due milestone and royalty payments if the combination product is commercialized, but no numbers were put in the press release, so it's impossible to know if BioSante traded upfront cash for a larger percentage on the back end.
Granted, the cancer vaccine program isn't BioSante's lead product. It'll live and die by its testosterone gels: LibiGel for female sexual dysfunction and Bio-T-Gel, which is partnered with Teva Pharmaceuticals
But the cancer vaccine has been pumped as the next Dendreon's
Better than nothing? I guess. Enough to get me excited about BioSante? Not really.
Pfizer is a Motley Fool Inside Value recommendation. Teva Pharmaceutical Industries is a Motley Fool Global Gains selection. The Fool owns shares of Abbott Laboratories and Teva Pharmaceutical Industries. Alpha Newsletter Account, LLC owns shares of Abbott Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.